查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1712496

全球骨坏死治疗市场 - 2025-2033

Global Osteonecrosis Treatment Market - 2025-2033
出版日期: | 出版商: DataM Intelligence | 英文 176 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

2024年全球骨坏死治疗市场规模达2.5322亿美元，预计到2033年将达到4.0301亿美元，在2025-2033年的预测期内复合年增长率为5.9%。

骨坏死，也称为缺血性坏死、无菌性坏死或缺血性骨坏死，是一种因骨软骨下区域血流中断而导致骨细胞死亡的退化性骨病变。这种疾病最常影响承重关节处长骨的骨骺，在严重的情况下，会破坏软骨下骨或导致整个关节塌陷。

股骨头、膝关节、距骨和肱骨头是骨坏死最常见的部位，而髋关节是最常受影响的关节。不太常见的是，它可以发生在其他骨骼中，例如腕骨或下颚骨。早期发现和介入对于有效治疗骨坏死至关重要。这项活动探讨了该疾病背后的原因和机制以及最常见受影响区域的表现和治疗方案。

市场动态：

驾驶员和约束装置

骨坏死发生率上升

骨坏死发生率的不断上升是全球骨坏死治疗市场扩张的重要驱动力。随着越来越多的人被诊断出患有这种疾病，对有效治疗方案的需求也随之增加，推动了市场的成长。全球人口老化是导致骨坏死病例增加的主要因素。老年人罹患骨坏死的风险更高，尤其是髋关节。根据世界卫生组织（WHO）的数据，到2030年，每6人中就有1人年龄在60岁或以上，到2050年，60岁以上人口数将达到21亿人。

骨坏死最常见于 60 岁及以上的人，其中髋关节最容易受到影响。创伤性损伤，尤其是道路交通事故造成的创伤，是导致骨坏死增加的主要原因，尤其是在年轻人身上。根据世界卫生组织（WHO）2023年12月的资料，每年约有119万人死于道路交通事故。道路交通伤害是5至29岁儿童和年轻人死亡的主要原因。随着外伤数量的增加，骨坏死病例的数量也会增加。这增加了对关节保护手术、截骨术和关节成形术等治疗方案的需求。

骨坏死最常影响髋部，但也可发生在肱骨、膝盖和距骨。这种症状在腕部较小的骨头（如月骨）中较不常见。虽然它也会影响下颚，但本综述重点关注骨科医生看到的更常见的形式。根据美国国家生物技术资讯中心 (NCBI) 2023 年 8 月的资料，在美国，10% 的全髋关节置换术是由于缺血性坏死 (AVN) 进行的，通常影响 30 至 65 岁的个人。

由于使用皮质类固醇、生活方式疾病、创伤和人口老化，骨坏死发生率不断上升，对全球骨坏死治疗市场产生了重大影响。这种日益加重的负担推动了药物和外科治疗的创新，使骨坏死管理成为骨科和再生医学行业中一个不断增长的领域。

与治疗相关的不良副作用

多种因素会增加双磷酸盐相关颚骨坏死（BRONJ）的风险，这可能会对全球骨坏死治疗市场造成限制。根据美国国家生物技术资讯中心（NCBI）2023年7月的资料，拔牙、牙周治疗、口腔植牙、使用假牙等牙科手术会加速骨转换，增加骨坏死的风险。癌症、化疗、低血红蛋白、糖尿病、肾透析、高血压、高脂血症和高胆固醇血症等疾病进一步增加了 BRONJ 的风险。

皮质类固醇、H2 阻断剂、抗血管生成剂（例如舒尼替尼、贝伐单抗）、促红血球生成素和环磷酰胺疗法等药物会影响骨骼代谢和免疫反应，从而增加 BRONJ 的风险。某些遗传因素，例如法呢基焦磷酸合成酶或 CYP2C8 的多态性，可能使个体易患双磷酸盐相关的骨坏死，尤其是在多发性骨髓瘤患者中。年龄、饮酒和吸烟会进一步增加骨坏死的可能性，使治疗选择变得复杂。

目录

第一章：市场介绍和范围

  • 报告目标
  • 报告范围和定义
  • 报告范围

第二章：高阶主管见解与关键要点

  • 市场亮点和战略要点
  • 主要趋势和未来预测
  • 按类型分类的程式码片段
  • 治疗片段
  • 依给药途径分类的片段
  • 按地区分类的片段

第三章：动态

  • 影响因素
    • 驱动程式
      • 骨坏死发生率上升
      • 医疗科技的进步
    • 限制
      • 与治疗相关的不良副作用
      • 手术治疗费用高昂
    • 机会
      • 对非侵入性治疗的需求
    • 影响分析

第四章：战略洞察与产业展望

  • 市场领导者和先驱者
    • 新兴先锋和杰出参与者
    • 拥有最大销售品牌的既定领导者
    • 拥有成熟产品的市场领导者
  • CXO 观点
  • 最新进展与突破
  • 监管和报销情况
    • 北美洲
    • 欧洲
    • 亚太地区
    • 南美洲
    • 中东和非洲
  • 波特五力分析
  • 供应链分析
  • 专利分析
  • SWOT分析
  • 未满足的需求和差距
  • 市场进入和扩张的推荐策略
  • 情境分析：最佳情况、基本情况和最坏情况预测
  • 定价分析和价格动态
  • 关键意见领袖

第五章：骨坏死治疗市场（按类型）

  • 创伤性
  • 非创伤性

第六章：骨坏死治疗市场（依治疗方法）

  • 非类固醇抗发炎药
    • 布洛芬
    • 萘普生钠
  • 血液稀释剂
    • 华法林
    • 依诺肝素
  • 降胆固醇药物
  • 骨质疏鬆症药物
  • 双磷酸盐
    • 阿崙膦酸钠
    • 利塞膦酸盐
    • 唑来膦酸
    • 伊班膦酸盐
  • 其他的

第七章：骨坏死治疗市场（依给药途径）

  • 口服
  • 肠外

第八章：骨坏死治疗市场，按区域市场分析和成长机会

  • 北美洲
    • 我们
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 西班牙
    • 义大利
    • 欧洲其他地区
  • 南美洲
    • 巴西
    • 阿根廷
    • 南美洲其他地区
  • 亚太
    • 中国
    • 印度
    • 日本
    • 韩国
    • 亚太其他地区
  • 中东和非洲

第九章：竞争格局与市场定位

  • 竞争概况和主要市场参与者
  • 市占率分析与定位矩阵
  • 策略伙伴关係、併购
  • 产品组合和创新的关键发展
  • 公司基准化分析

第十章：公司简介

  • Pfizer Inc.
    • 公司概况
    • 产品组合
      • 产品描述
      • 产品关键绩效指标 (KPI)
      • 历史和预测产品销售
      • 产品销售量
    • 财务概览
      • 公司收入
      • 地区收入份额
      • 收入预测
    • 关键进展
      • 併购
      • 关键产品开发活动
      • 监管部门批准等
    • SWOT分析
  • Haleon Group of Companies
  • BASF Corporation
  • Johnson & Johnson
  • Bayer AG
  • Sanofi
  • Upsher-Smith Laboratories, LLC.
  • Merck & Co., Inc
  • Procter & Gamble Pharmaceuticals, Inc.
  • Novartis AG
  • Eugia US
  • Dr. Reddy's Laboratories
  • Amgen Inc.

第 11 章：假设与研究方法

  • 资料收集方法
  • 数据三角测量
  • 预测技术
  • 数据验证和确认

第 12 章：附录

简介目录
Product Code: PH7228

The global osteonecrosis treatment market reached US$ 253.22 million in 2024 and is expected to reach US$ 403.01 million by 2033, growing at a CAGR of 5.9 % during the forecast period of 2025-2033.

Osteonecrosis, also referred to as avascular necrosis, aseptic necrosis, or ischemic bone necrosis, is a degenerative bone condition caused by the interruption of blood flow to the bone's subchondral area, leading to the death of bone cells. This condition most commonly affects the epiphysis of long bones at weight-bearing joints and, in severe cases, can destroy the subchondral bone or cause the collapse of an entire joint.

The femoral head, knee, talus, and humeral head are the most frequent sites for osteonecrosis, with the hip being the most commonly affected joint. Less commonly, it can occur in other bones such as the carpus or jaw. Early detection and intervention are crucial for the effective management of osteonecrosis. This activity explores the causes and mechanisms behind the disease and the presentation and treatment options for the most commonly affected areas.

Market Dynamics: Drivers & Restraints

Rising Incidence of Osteonecrosis

The growing incidence of osteonecrosis is a significant driver for expanding the global osteonecrosis treatment market. As more individuals are diagnosed with this condition, the demand for effective treatment options increases, fueling market growth. The aging global population is a major factor contributing to the rising number of osteonecrosis cases. Older individuals are at a higher risk of developing osteonecrosis, particularly in the hip joint. According to the World Health Organization (WHO), by 2030, 1 in 6 people will be aged 60 or older, and by 2050, the number of people aged 60 and above will reach 2.1 billion.

Osteonecrosis is most common in individuals aged 60 and above, with the hip joint being the most frequently affected. Traumatic injuries, particularly from road accidents, are key contributors to the rise in osteonecrosis, especially in younger individuals. As per World Health Organization (WHO) data in December 2023, around 1.19 million people die annually due to road traffic accidents. Road traffic injuries are the leading cause of death among children and young adults aged 5 to 29 years. As the number of traumatic injuries increases, so will the number of osteonecrosis cases. This increases the demand for treatment options like joint preservation surgery, osteotomy, and arthroplasty.

Osteonecrosis most commonly affects the hip but can also occur in the humerus, knee, and talus. It is less frequently seen in the smaller bones of the wrist, like the lunate. While it can also impact the jaw, this review focuses on the more common forms seen by orthopedic surgeons. According to the National Center for Biotechnology Information (NCBI) data in August 2023, in the United States, 10% of total hip arthroplasties are performed due to avascular necrosis (AVN), typically affecting individuals aged 30 to 65.

The increasing incidence of osteonecrosis, driven by corticosteroid use, lifestyle diseases, trauma, and an aging population, is significantly impacting the global osteonecrosis treatment market. This rising burden is pushing forward innovations in both pharmacological and surgical treatments, making osteonecrosis management a growing segment within the orthopedic and regenerative medicine industries.

Adverse Side Effects Associated with Treatment

Several factors increase the risk of developing bisphosphonate-related osteonecrosis of the jaw (BRONJ), which can act as a restraint in the global osteonecrosis treatment market. According to the National Center for Biotechnology Information (NCBI) data in July 2023, dental surgeries such as tooth extractions, periodontal treatments, oral implants, and the use of dentures can heighten bone turnover and increase the risk of osteonecrosis. Conditions like cancer, chemotherapy, low hemoglobin, diabetes, renal dialysis, hypertension, hyperlipidemia, and hypercholesterolemia further elevate the risk of developing BRONJ.

Drugs such as corticosteroids, H2 blockers, antiangiogenic agents (e.g., sunitinib, bevacizumab), erythropoietin, and cyclophosphamide therapy can increase the risk of BRONJ by affecting bone metabolism and immune response. Certain genetic factors, such as polymorphisms in farnesyl pyrophosphate synthase or CYP2C8, may predispose individuals to bisphosphonate-associated osteonecrosis, particularly in patients with multiple myeloma. Age, alcohol consumption, and tobacco use can further increase the likelihood of developing osteonecrosis, complicating treatment options.

Segment Analysis

The global osteonecrosis treatment market is segmented based on type, treatment, route of administration, and region.

Treatment:

The non-steroidal anti-inflammatory drugs segment in treatment is expected to dominate the global osteonecrosis treatment market with the highest market share

Non-steroidal anti-inflammatory drugs (NSAIDs) are widely used as a first-line treatment to manage pain and inflammation associated with osteonecrosis, a condition characterized by the death of bone tissue due to reduced blood supply. NSAIDs work by inhibiting cyclooxygenase (COX) enzymes, reducing the production of prostaglandins, which are responsible for inflammation and pain. In osteonecrosis, NSAIDs are primarily prescribed to provide symptomatic relief and to manage associated conditions such as arthritis.

The increasing prevalence of osteonecrosis due to factors such as prolonged corticosteroid use, alcohol consumption, trauma, and autoimmune diseases is driving demand for NSAIDs.Due to concerns over opioid addiction, many healthcare providers prefer NSAIDs as a safer alternative for pain management.NSAIDs are available in oral, topical, and injectable forms, offering flexibility in administration for different patient needs. With an aging population prone to bone-related conditions like osteoporosis and osteonecrosis, NSAID demand is expected to grow. These factors have solidified the segment's position in the global osteonecrosis treatment market.

Geographical Analysis

North America is expected to hold a significant position in the global osteonecrosis treatment market, with the highest market share

Osteonecrosis is a significant cause of hip arthroplasties in the U.S., affecting individuals primarily between the ages of 30 and 65. Around 10% of total hip replacements are due to avascular necrosis, indicating a strong demand for treatment solutions. The increasing number of elderly individuals in North America contributes to the demand for osteonecrosis treatments. In the U.S., 17% of the population was 65 or older in 2022, and this demographic is at a higher risk of developing osteonecrosis, further driving market growth.

The development of innovative treatment options, such as ozone injections for medication-related osteonecrosis of the jaw (MRONJ), is expected to boost the market. These treatments provide effective alternatives to surgical intervention for complex cases. The market has seen several approvals for osteonecrosis-related medications. For instance, in June 2022, Strides Pharma received FDA approval for its Ibuprofen suspension. The U.S. market for this product is estimated to be approximately $41 million, and it will be produced at the company's facility in Bengaluru. Thus, the above factors are consolidating the region's position as a dominant force in the global osteonecrosis treatment market.

Competitive Landscape

The major global players in the osteonecrosis treatment market include Pfizer Inc., Haleon Group of Companies, BASF Corporation, Johnson & Johnson, Bayer AG, Sanofi, Upsher-Smith Laboratories, LLC., Merck & Co., Inc., Procter & Gamble Pharmaceuticals, Inc., Novartis AG, Eugia US, Dr. Reddy's Laboratories, and Amgen Inc. among others.

Key Developments

  • In March 2023, Perrigo Company plc, a leading provider of Consumer Self-Care Products, announced that it had received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Acetaminophen and Ibuprofen Tablets, 250 mg/125 mg.

Why Purchase the Report?

  • Pipeline & Innovations: Reviews ongoing clinical trials and product pipelines and forecasts upcoming advancements in medical devices and pharmaceuticals.
  • Product Performance & Market Positioning: Analyzed product performance, market positioning, and growth potential to optimize strategies.
  • Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
  • Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
  • Market Updates & Industry Changes: This covers recent regulatory changes, new policies, and emerging technologies.
  • Competitive Strategies: Analyze competitor strategies, market share, and emerging players.
  • Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
  • Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
  • Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
  • Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
  • Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
  • Post-market Surveillance: Uses post-market data to enhance product safety and access.
  • Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The global osteonecrosis treatment market report delivers a detailed analysis with 71 key tables, more than 56 visually impactful figures, and 176 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2024

  • Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
  • Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
  • Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
  • Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
  • Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
  • Supply Chain: Distribution and Supply Chain Managers.
  • Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
  • Academic & Research: Academic Institutions.

Table of Contents

1. Market Introduction and Scope

  • 1.1. Objectives of the Report
  • 1.2. Report Coverage & Definitions
  • 1.3. Report Scope

2. Executive Insights and Key Takeaways

  • 2.1. Market Highlights and Strategic Takeaways
  • 2.2. Key Trends and Future Projections
  • 2.3. Snippet by Type
  • 2.4. Snippet by Treatment
  • 2.5. Snippet by Route of Administration
  • 2.6. Snippet by Region

3. Dynamics

  • 3.1. Impacting Factors
    • 3.1.1. Drivers
      • 3.1.1.1. Rising Incidence of Osteonecrosis
      • 3.1.1.2. Advancements in Medical Technology
    • 3.1.2. Restraints
      • 3.1.2.1. Adverse Side Effects Associated with Treatment
      • 3.1.2.2. High Costs Associated with Surgical Treatments
    • 3.1.3. Opportunity
      • 3.1.3.1. Demand for Non-Invasive Treatments
    • 3.1.4. Impact Analysis

4. Strategic Insights and Industry Outlook

  • 4.1. Market Leaders and Pioneers
    • 4.1.1. Emerging Pioneers and Prominent Players
    • 4.1.2. Established leaders with the largest-selling Brand
    • 4.1.3. Market leaders with established Product
  • 4.2. CXO Perspectives
  • 4.3. Latest Developments and Breakthroughs
  • 4.4. Regulatory and Reimbursement Landscape
    • 4.4.1. North America
    • 4.4.2. Europe
    • 4.4.3. Asia Pacific
    • 4.4.4. South America
    • 4.4.5. Middle East & Africa
  • 4.5. Porter's Five Forces Analysis
  • 4.6. Supply Chain Analysis
  • 4.7. Patent Analysis
  • 4.8. SWOT Analysis
  • 4.9. Unmet Needs and Gaps
  • 4.10. Recommended Strategies for Market Entry and Expansion
  • 4.11. Scenario Analysis: Best-Case, Base-Case, and Worst-Case Forecasts
  • 4.12. Pricing Analysis and Price Dynamics
  • 4.13. Key Opinion Leaders

5. Osteonecrosis Treatment Market, By Type

  • 5.1. Introduction
    • 5.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 5.1.2. Market Attractiveness Index, By Type
  • 5.2. Traumatic*
    • 5.2.1. Introduction
    • 5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 5.3. Nontraumatic

6. Osteonecrosis Treatment Market, By Treatment

  • 6.1. Introduction
    • 6.1.1. Analysis and Y-o-Y Growth Analysis (%), By Treatment
    • 6.1.2. Market Attractiveness Index, By Treatment
  • 6.2. Non-Steroidal Anti-Inflammatory Drugs*
    • 6.2.1. Introduction
    • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
    • 6.2.3. Ibuprofen
    • 6.2.4. Naproxen Sodium
  • 6.3. Blood Thinners
    • 6.3.1. Warfarin
    • 6.3.2. Enoxaparin
  • 6.4. Cholesterol-Lowering Drugs
  • 6.5. Osteoporosis Drugs
  • 6.6. Bisphosphonates
    • 6.6.1. Alendronate
    • 6.6.2. Risedronate
    • 6.6.3. Zoledronic Acid
    • 6.6.4. Ibandronate
  • 6.7. Others

7. Osteonecrosis Treatment Market, By Route of Administration

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 7.1.2. Market Attractiveness Index, By Route of Administration
  • 7.2. Oral*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Parenteral

8. Osteonecrosis Treatment Market, By Regional Market Analysis and Growth Opportunities

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 8.1.2. Market Attractiveness Index, By Region
  • 8.2. North America
    • 8.2.1. Introduction
    • 8.2.2. Key Region-Specific Dynamics
    • 8.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 8.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
    • 8.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 8.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 8.2.6.1. U.S.
      • 8.2.6.2. Canada
      • 8.2.6.3. Mexico
  • 8.3. Europe
    • 8.3.1. Introduction
    • 8.3.2. Key Region-Specific Dynamics
    • 8.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 8.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
    • 8.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 8.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 8.3.6.1. Germany
      • 8.3.6.2. U.K.
      • 8.3.6.3. France
      • 8.3.6.4. Spain
      • 8.3.6.5. Italy
      • 8.3.6.6. Rest of Europe
  • 8.4. South America
    • 8.4.1. Introduction
    • 8.4.2. Key Region-Specific Dynamics
    • 8.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 8.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
    • 8.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 8.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 8.4.6.1. Brazil
      • 8.4.6.2. Argentina
      • 8.4.6.3. Rest of South America
  • 8.5. Asia-Pacific
    • 8.5.1. Introduction
    • 8.5.2. Key Region-Specific Dynamics
    • 8.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 8.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
    • 8.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 8.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 8.5.6.1. China
      • 8.5.6.2. India
      • 8.5.6.3. Japan
      • 8.5.6.4. South Korea
      • 8.5.6.5. Rest of Asia-Pacific
  • 8.6. Middle East and Africa
    • 8.6.1. Introduction
    • 8.6.2. Key Region-Specific Dynamics
    • 8.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 8.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
    • 8.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration

9. Competitive Landscape and Market Positioning

  • 9.1. Competitive Overview and Key Market Players
  • 9.2. Market Share Analysis and Positioning Matrix
  • 9.3. Strategic Partnerships, Mergers & Acquisitions
  • 9.4. Key Developments in Product Portfolios and Innovations
  • 9.5. Company Benchmarking

10. Company Profiles

  • 10.1. Pfizer Inc.*
    • 10.1.1. Company Overview
    • 10.1.2. Product Portfolio
      • 10.1.2.1. Product Description
      • 10.1.2.2. Product Key Performance Indicators (KPIs)
      • 10.1.2.3. Historic and Forecasted Product Sales
      • 10.1.2.4. Product Sales Volume
    • 10.1.3. Financial Overview
      • 10.1.3.1. Company Revenue
      • 10.1.3.2. Geographical Revenue Shares
      • 10.1.3.3. Revenue Forecasts
    • 10.1.4. Key Developments
      • 10.1.4.1. Mergers & Acquisitions
      • 10.1.4.2. Key Product Development Activities
      • 10.1.4.3. Regulatory Approvals, etc.
    • 10.1.5. SWOT Analysis
  • 10.2. Haleon Group of Companies
  • 10.3. BASF Corporation
  • 10.4. Johnson & Johnson
  • 10.5. Bayer AG
  • 10.6. Sanofi
  • 10.7. Upsher-Smith Laboratories, LLC.
  • 10.8. Merck & Co., Inc
  • 10.9. Procter & Gamble Pharmaceuticals, Inc.
  • 10.10. Novartis AG
  • 10.11. Eugia US
  • 10.12. Dr. Reddy's Laboratories
  • 10.13. Amgen Inc.

LIST NOT EXHAUSTIVE

11. Assumptions and Research Methodology

  • 11.1. Data Collection Methods
  • 11.2. Data Triangulation
  • 11.3. Forecasting Techniques
  • 11.4. Data Verification and Validation

12. Appendix

  • 12.1. About Us and Services
  • 12.2. Contact Us